Koers Chinook Tyee Industry Ltd Toronto S.E.
Aandelen
GBI.H
CA16961T2083
Farmaceutische producten
Omzet 2021 | 453K 329K 308K | Omzet 2022 | - | Marktkapitalisatie | 3,43 mln. 2,49 mln. 2,34 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -3 mln. -2,18 mln. -2,04 mln. | Nettowinst (verlies) 2022 | -1 mln. -726K -681K | EV/omzet 2021 | 24,5 x |
Nettoschuld 2021 | 1,87 mln. 1,36 mln. 1,28 mln. | Nettoschuld 2022 | 3,15 mln. 2,29 mln. 2,14 mln. | EV/omzet 2022 | - |
K/w-verhouding 2021 |
-2,14
x | K/w-verhouding 2022 |
-1,79
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 74,11% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Tom Kusumoto
CEO | Chief Executive Officer | 54 | 14-12-12 |
Director/Board Member | 72 | 05-12-18 | |
Investor Relations Contact | - | 01-01-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Tom Kusumoto
CEO | Chief Executive Officer | 54 | 14-12-12 |
Director/Board Member | 72 | 05-12-18 | |
Frank Otto
BRD | Director/Board Member | - | 11-05-22 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+39,33% | 6,01 mld. | |
-18,38% | 4,4 mld. | |
-9,17% | 3,17 mld. | |
+3,98% | 3,07 mld. | |
-3,41% | 2,51 mld. | |
+48,74% | 1,88 mld. | |
-4,82% | 1,73 mld. | |
-1,24% | 1,65 mld. | |
-8,96% | 1,58 mld. |